Piramal Pharma Limited has reported its audited financial results for the year ended March 31, 2026. The company has announced the re-appointment of key leadership, including Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director. Additionally, the company appointed Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026, and confirmed a change in its registered office address.
Fiscal Year 2026 Financial Performance
For the financial year ended March 31, 2026, Piramal Pharma Limited reported standalone revenue from operations of ₹4,782.01 crore, with a profit after tax of ₹700.01 crore. On a consolidated basis, the company reported annual revenue of ₹8,869.08 crore for the same period. The board has approved these results, reflecting the company’s ongoing focus on operational efficiency and strategic growth across its global development and manufacturing footprint.
Leadership Continuity and Appointments
The company announced significant leadership updates to ensure stability and long-term vision. Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, for a further term of 3 years effective April 1, 2027. Similarly, Mr. Peter DeYoung has been re-appointed as Whole-Time Director and Executive Director for 3 years, starting October 6, 2026. Furthermore, independent directors Mr. Sridhar Gorthi and Mr. Peter Stevenson have both been re-appointed for second terms of 5 years, effective March 30, 2027.
Strategic Personnel and Administrative Changes
As part of its organizational strengthening, the company appointed Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026, succeeding Ms. Pratibha Mishra. Additionally, the company has announced a shift in its registered office address to the Ananta Building, Piramal Corporate Park, Kurla (West), Mumbai, effective April 30, 2026.
Source: BSE
